Virus News and Research

Latest Virus News and Research

CEL-SCI initiates Multikine Phase III clinical trial for head and neck cancer in Hungary

CEL-SCI Corporation announced today that it has commenced its Phase III clinical trial for Multikine®, the Company's flagship immunotherapy, at the National Institute of Oncology in Budapest, Hungary. Enrollment is expected to start soon in this center. The study is already ongoing at twelve clinical sites in the United States, Canada, Poland and India.

13 Jun 2011

Alios, Vertex sign worldwide license agreement to develop new hepatitis C combination medicines

Vertex Pharmaceuticals Incorporated and Alios BioPharma, Inc. today announced an exclusive worldwide licensing agreement that will add two distinct nucleotide analogues to Vertex's hepatitis C portfolio.

13 Jun 2011

S. African government program reduced MTCT HIV transmission rate to 3.5%, study shows

The South African government's program to prevent mother-to-child transmission (PMTCT) of HIV has reduced the rate of virus transmission to about 3.5 percent, "potentially sparing some 67,000 babies from HIV infection," according to research presented on Wednesday by the Medical Research Council at the 5th South African AIDS Conference in Durban, Health-e/allAfrica.com reports.

13 Jun 2011

NIAID awards Biota $2.9M grant for development of lead candidate for C. difficile

Biota Holdings Limited advises that its wholly owned subsidiary, Biota Scientific Management Pty Ltd, has been awarded a grant to fund the preclinical development of a lead candidate for the treatment of Clostridium difficile (C. difficile).

10 Jun 2011

Swine flu may have been more widespread in Scotland than previously believed, study says

Up to two million people in Scotland may have been infected with swine flu during the outbreak of winter 2009-2010, making the flu much more widespread than previously thought, according to a study published by researchers from the University of Edinburgh in PLoS One, BBC News reports.

10 Jun 2011

Quest Diagnostics receives MDEA gold award for Simplexa/3M technology

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, today announced that its Simplexa molecular diagnostic test on the 3M Integrated Cycler won a gold award in the in vitro diagnostics category at the 2011 MDEA awards ceremony yesterday in New York City.

From Quest Diagnostics 10 Jun 2011

Global initiative to prevent HIV in babies

World leaders met to decide on the launch of a global plan with the goal of ensuring that every baby is born HIV-free by 2015 and that their mothers with the HIV virus live to raise them.

9 Jun 2011

Ilex, Cerus partner to distribute INTERCEPT Blood System in Israel and South Africa

Cerus Corporation today announced today that it has entered into agreements with Ilex Biotech Limited to distribute Cerus' INTERCEPT Blood System for platelets and plasma in South Africa and Israel.

9 Jun 2011

Adults with herpes zoster may face higher risk of multiple sclerosis

Taiwanese investigators have found that there can be a significantly higher risk of multiple sclerosis (MS) occurring in the year following a shingles, or herpes zoster, attack.

9 Jun 2011

Adjuvant combination generates memory CD8 T cells which could kill infected cells

Researchers at National Jewish Health have discovered how to prime a second arm of the immune system to potentially boost influenza vaccine effectiveness. A combination of two adjuvants, chemicals used to boost the effectiveness of some vaccines, induced CD8, or killer, T cells to join antibodies in response to influenza infection.

9 Jun 2011

Neurologix reports new results from NLX-P101 Phase 2 trial against Parkinson's disease

Neurologix, Inc. announced today several new results from the Company's successful Phase 2 clinical trial for its novel, investigational gene therapy NLX-P101 for the treatment of Parkinson's disease (PD) as part of a comprehensive presentation of study findings to the National Institutes of Health (NIH) Recombinant DNA Advisory Committee.

9 Jun 2011

Rockefeller, Scripps Research develop first genetically humanized mouse model for hepatitis C

Scientists at Rockefeller University and The Scripps Research Institute have developed the first genetically humanized mouse model for hepatitis C, an achievement that will enable researchers to test molecules that block entry of the hepatitis C virus into cells as well as potential vaccine candidates. The finding is reported in the June 9 issue of the journal Nature.

9 Jun 2011

Hepatitis C virus (HCV)-associated liver disease after liver transplantation

Hepatitis C virus (HCV)-associated liver disease continues to be the most common indication for liver transplantation (LT) in the United States accounting for nearly 50% of all liver transplants. Recurrence is universal in patients viremic at the time of transplantation with histological hepatitis developing in the majority of patients. Although the natural history of recurrent HCV is difficult to predict, it is widely accepted that cirrhosis from recurrent HCV occurs in up to 30% of patients within five years of transplantation.

8 Jun 2011

IAS calls on leaders to ensure inclusion of HIV cure research into international AIDS agenda

As world leaders meet this week to review progress and chart the future course of the global AIDS response at the 2011 UN General Assembly High-Level Meeting on AIDS in New York, the International AIDS Society (IAS) calls on leaders to ensure the inclusion of HIV cure research and its global strategy into the international HIV agenda and in all discussions, political decisions and funding strategies.

8 Jun 2011

GSK, Crucell to test second-generation malaria vaccine

GlaxoSmithKline and drug company Crucell, a division of Johnson & Johnson, will collaborate with the PATH Malaria Vaccine Initiative to test a second-generation malaria vaccine "within the next couple of months," Reuters reports.

8 Jun 2011

Pharmasset expands PSI-7977 clinical trial for treatment of chronic hepatitis C

Pharmasset, Inc. announced today the addition of three treatment cohorts to the ELECTRON trial of PSI-7977, a nucleotide analog polymerase inhibitor, for the treatment of chronic hepatitis C (HCV).

8 Jun 2011

Vaccine candidate produces immune response to antigen in all strains of influenza A

A universal influenza vaccine targeting a protein common to all strains of influenza A has safely produced an immune response in humans. If proven effective, the vaccine could eliminate the practice of creating a new flu vaccine annually to match predicted strains, with major implications for global health.

8 Jun 2011

MicroDose completes atropine inhaler Phase I study on nerve agent poisoning

MicroDose Therapeutx Inc. today announced that its collaborators at the University of Pittsburgh (Pitt) have completed a Phase I study at the University of Pittsburgh Medical Center with atropine sulfate delivered from the MicroDose proprietary dry powder inhaler (DPI).

8 Jun 2011

Hepatitis C patients with chronic liver disease may benefit from drinking coffee during treatment

Advanced hepatitis C patients with chronic liver disease may benefit from drinking coffee during treatment, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.

8 Jun 2011

NanoViricides' anti-influenza drug development studies to be presented at TechConnect World 2011

NanoViricides, Inc. announced today that it has been invited to present its anti-influenza drug development studies at the TechConnect World 2011 Conferences and Expo.

7 Jun 2011

Virus News and Research

Latest Virus News and Research

CEL-SCI initiates Multikine Phase III clinical trial for head and neck cancer in Hungary

Alios, Vertex sign worldwide license agreement to develop new hepatitis C combination medicines

S. African government program reduced MTCT HIV transmission rate to 3.5%, study shows

NIAID awards Biota $2.9M grant for development of lead candidate for C. difficile

Swine flu may have been more widespread in Scotland than previously believed, study says

Quest Diagnostics receives MDEA gold award for Simplexa/3M technology

Global initiative to prevent HIV in babies

Ilex, Cerus partner to distribute INTERCEPT Blood System in Israel and South Africa

Adults with herpes zoster may face higher risk of multiple sclerosis

Adjuvant combination generates memory CD8 T cells which could kill infected cells

Neurologix reports new results from NLX-P101 Phase 2 trial against Parkinson's disease

Rockefeller, Scripps Research develop first genetically humanized mouse model for hepatitis C

Hepatitis C virus (HCV)-associated liver disease after liver transplantation

IAS calls on leaders to ensure inclusion of HIV cure research into international AIDS agenda

GSK, Crucell to test second-generation malaria vaccine

Pharmasset expands PSI-7977 clinical trial for treatment of chronic hepatitis C

Vaccine candidate produces immune response to antigen in all strains of influenza A

MicroDose completes atropine inhaler Phase I study on nerve agent poisoning

Hepatitis C patients with chronic liver disease may benefit from drinking coffee during treatment

NanoViricides' anti-influenza drug development studies to be presented at TechConnect World 2011

A new way of characterising biomolecules eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in